Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZL006 是一种 nNOS/PSD-95 相互作用抑制剂,能够抑制 NMDA 受体介导的 NO 合成。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 248 | 现货 | ||
2 mg | ¥ 355 | 现货 | ||
5 mg | ¥ 561 | 现货 | ||
10 mg | ¥ 813 | 现货 | ||
25 mg | ¥ 1,650 | 现货 | ||
50 mg | ¥ 2,660 | 现货 | ||
100 mg | ¥ 4,660 | 现货 | ||
200 mg | ¥ 6,490 | 现货 | ||
500 mg | ¥ 9,670 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 638 | 现货 |
产品描述 | ZL006 is an effective inhibitor of nNOS/PSD-95 interaction. ZL006 also inhibits NMDA receptor-mediated NO synthesis. |
体外活性 | ZL006 growth inhibition of BCECs is not found at a low concentration of 0.001, 0.01, 0.1, 1, and 10 μg/mL. The cytotoxicity of T7-P-LPs/ZL006 is obviously enhanced at the concentration of 10 μg/mL. Cellular uptake of ZL006 loads P-LPs and T7-P-LPs after incubation for 0.5 h at the concentrations range from 100 μg/mL to 600 μg/mL in BCECs [1][2]. |
体内活性 | T7-P-LPs/ZL006 displays a significant enhance in drug accumulation in the brain tissue due to its better brain targeting delivery compared with P-LPs/ZL006 and free ZL006. P-LPs/ZL006 and T7-P-LPs/ZL006 show a significant decrease in drug accumulation in the liver and kidney compared with free ZL006 [1]. |
分子量 | 328.15 |
分子式 | C14H11Cl2NO4 |
CAS No. | 1181226-02-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 29 mg/mL (88.37 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.0474 mL | 15.2369 mL | 30.4739 mL | 76.1847 mL |
5 mM | 0.6095 mL | 3.0474 mL | 6.0948 mL | 15.2369 mL | |
10 mM | 0.3047 mL | 1.5237 mL | 3.0474 mL | 7.6185 mL | |
20 mM | 0.1524 mL | 0.7618 mL | 1.5237 mL | 3.8092 mL | |
50 mM | 0.0609 mL | 0.3047 mL | 0.6095 mL | 1.5237 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ZL006 1181226-02-7 Membrane transporter/Ion channel Neuroscience NMDAR iGluR Ionotropic glutamate receptors ZL 006 Inhibitor inhibit ZL-006 inhibitor